These findings counter clinical trial results published in June which found that Paxlovid was safe to take but did not lessen long COVID symptoms, the UCSF researchers noted. Those earlier trial ...

Paxlovid includes two pills called nirmatrelvir and ritonavir. Nirmatrelvir is an antiviral. This class of drugs stops SARS-COV-2, or the virus that causes COVID, from replicating in the body.

Paxlovid is recommended for use within five days of COVID-19 symptoms when someone tests positive for the virus. The treatment is a round of two drugs — two nirmatrelvir pills and one ritonavir ...

One of the medications to be affected includes Paxlovid, a treatment for COVID-19. The price hikes will also affect costs for Bristol Myers Squibb’s cancer cell therapies Abecma and Breyanzi as ...

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

Paxlovid, one of the most well-known treatments for COVID-19, has also been shown to ease symptoms of some patients with long COVID — and new research suggests the antiviral medication could ...

Can Paxlovid treat long COVID? A new report suggests it might help some patients, but which patients might benefit remains unclear. The report, published last week in the journal Communications ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Medicare beneficiaries can receive Paxlovid at no cost through February 28, 2025. Paxlovid has become a pivotal treatment for COVID-19, particularly for individuals at high risk of severe illness.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.